Cellectar Biosciences
CLRB
39 hedge funds and large institutions have $36.9M invested in Cellectar Biosciences in 2020 Q4 according to their latest regulatory filings, with 26 funds opening new positions, 5 increasing their positions, 2 reducing their positions, and 6 closing their positions.
3,413% more capital inflows, than outflows
Capital inflows: $22.5M | Capital outflows: $642K
333% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 6
150% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 2
95% more funds holding
Funds holding: 20 → 39 (+19)
25.97% more ownership
Funds ownership: 12.97% → 38.93% (+26%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Consonance Capital Management
New York
|
+$6.24M |
| 2 |
Maven Securities
St Helier,
Jersey
|
+$2.64M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.21M |
| 4 |
Sio Capital Management
New York
|
+$1.48M |
| 5 |
6CM
683 Capital Management
New York
|
+$1.42M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$261K |
| 2 |
Worth Venture Partners
Fort Lee,
New Jersey
|
-$218K |
| 3 |
Quilter Plc
London,
United Kingdom
|
-$72K |
| 4 |
Wedbush Securities
Los Angeles,
California
|
-$56K |
| 5 |
Squarepoint
New York
|
-$22K |
CLRB Hedge Fund Activity: Q4 2020 in Review
39 of the 5,678 institutional investors tracked by Wall St. Rank reported a position in Cellectar Biosciences (CLRB) for Q4 2020, worth a combined $36.9M — up 762% from $4.28M a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new CLRB positions and 6 closed out — a net gain of 20 holders — while 5 added to existing stakes and 2 trimmed.
The largest buyer was Consonance Capital Management, opening a new position worth an estimated $6.24M. The largest seller was Renaissance Technologies, cutting an estimated $261K.
- 39 institutional investors held Cellectar Biosciences (CLRB) as of Q4 2020, up from 20 in Q3 2020.
- Funds reported $36.9M of Cellectar Biosciences stock for Q4 2020, up 762% quarter-over-quarter.
- 26 funds opened new Cellectar Biosciences positions in Q4 2020 and 6 closed out, a net change of +20 holders.
- The largest Cellectar Biosciences buyer in Q4 2020 was Consonance Capital Management, an estimated $6.24M added.
- The largest Cellectar Biosciences seller in Q4 2020 was Renaissance Technologies, an estimated $261K sold.
Based on aggregated 13F filings for Q4 2020.